Translation of pharmacogenetic knowledge into cancer therapeutics

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 9, 2007, Pages 698-706

  Yong, Wei Peng ^a   Innocenti, Federico ^b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer therapeutics; Chemotherapy; Pharmacogenetics; Polymorphisms

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C2; ANTINEOPLASTIC AGENT; ASPARAGINASE; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; CYTOCHROME P450 2D6; DAUNORUBICIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; IRINOTECAN; K RAS PROTEIN; MERCAPTOPURINE; MULTIDRUG RESISTANCE PROTEIN 1; PLACEBO; PREDNISOLONE; SULFOTRANSFERASE 1A1; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE; VINCRISTINE; ANTINEMATODAL AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG LABELING; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; GILBERT DISEASE; HAPLOTYPE; HUMAN; LUNG CANCER; MONOTHERAPY; MUTATIONAL ANALYSIS; MYELOID LEUKEMIA; NEUTROPENIA; PHARMACOGENETICS; PHENOTYPIC VARIATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; UNITED STATES; FEMALE; GENETICS; MALE; METABOLISM; METHODOLOGY; NEOPLASM; STANDARD;

ANTINEMATODAL AGENTS; DRUG LABELING; FEMALE; HUMANS; MALE; NEOPLASMS; PHARMACOGENETICS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 38449109707     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Cerri E, Falcone A, Innocenti F. Cancer pharmacogenomics: germline DNA, tumor DNA, or both? Pharmacogenomics. In press.
2. Mathijssen RH, Marsh S, Karlsson MO, et al. Itinorecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res. 2003;9:3246-3253.
3. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet. 1999;56:247-258.
4. Carson PE, Alving AS, Flanagan CL, Ickes CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science, 1956; 124(3220):484-485.
5. Bonicke R, Reif W. (Enzymatic inactivation of isonicetinic acid hydrizide in human and animal organism. J. Naunyn Schmiedeberes Arch Exp Pathol Pharmakol. 1953;220:321-323.
6. Lehmann H, Ryan E. The familial incidence of low pseudochollnesterase level Lancet. 1956;271(6934):124.
7. Hughes HB, Biehl JP, Jones AP, Schmidt LH. Metabolism of Isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc. 1954;70:266-273.
8. Lyss AP, Lilenbaum RC, Harris BE, Diasio RB. Severe 5-fluorourac toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest. 1993;11:239-240.
9. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest. 1988;81:47-51.
10. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered metcaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 1991;119:985-989.
11. Evans WE, Hon YY, Bomgaars L, et al, Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001;19:2293-2301.
12. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001-2008.
13. Weinshilboum RM, Sladek SL. Mercaptopurine Pharmacogenerics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1990;32:651-662.
14. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol. 1998;9:845-847.
15. Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol. 1997;8:1049-1051.
16. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucutonosyltransferase 1A1 gene predict die risk of severe neutropenia of irinotecan. J Clin Oncol. 2004:22:1382-1388.
17. Sachidanandam R, Weissman D, Schmidt SC, et al. A map ofhurnan genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409:928-933.
18. Ji Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-39.
19. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113-121.
20. Goldstein DB, Cavalleri GL. Genomics: understanding human diversity. Nature 2005;437(7063):1241-1242.
21. A haplotype map of the human genome. Nature. 2005;437(7063):1299-1320.
22. Henriksson E, Baldetorp B, Borg A, et al. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol. 2006:45:300-305.
23. Haston CK, Tomko TG, Godin N. Kerckhoff L, Hallett MT: Murine candidate bleomycin induced pulmonary fibrosis susceptibility genes identified by gene expression and sequence analysis of linkage regions. J Med Genet. 2005;42: 464-473.
24. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533-542.
25. Lugthart S, Cheok MH, den Boer ML, et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell. 2005;7:375-386.
26. Schmidt S, Rainer J, Riml S, et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood. 2006;107:2061-2069.
27. Waiters JW Kraja A, Meucci MA, Province MA, McLeod HL. Genome-wide discover of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A. 2004; 101:11809-11814.
28. Dolan ME, Newbold KG, Nagasubramanian R, et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 2004;64:4353-4356.
29. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436(7047):117-122.
30. Pfeifer D, Pantic M, Skarulla I, et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood. 2007;109:1202-1210.
31. Walker BA, Leone PE, Jenner MW, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood, 2006;108:1733-1743.
32. Zhao X, Weir BA, LaFramboise T, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 2005;65:5561-5570.
33. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999;354:34-39.
34. Relling MV, Yanishevski Y, Nemec J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute mycloid leukemia. Leukemia. 1998:12:346-352.
35. Reing MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93:2817-2823.
36. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood adute lymphoblastic leukaemia. Lancet. 1990;336:225-229.
37. Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA. 2005;293:1485-1489.
38. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus: implications for clinical pharmacogenomics. Pharmacogenomics. 2002;3:89-98.
39. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharma-cogenetics. 2004;14:407-417.
40. Tai HL, Fessing MY, Bonten EJ, et al. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferasce (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics. 1999;9:641-650.
41. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of chiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*,3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A. 1997;94:6444-6449.
42. McLeod HL, Krynetski EY, Wilimas JA, Evans WE. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics. 1995;5:281-286.
43. Humerickhouse R, Lohrbarch K, Li L, Boston WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 2000;60:1189-1192.
44. Bosma PJ, Chowdbury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome, N Engl J Med. 1995;333:1171-1175.
45. Iyer L, King CD, Whitington PF, et al. Genetic predisposition i to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998;101:847-854.
46. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet. 1996;347:578-581.
47. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A. 1998;95:8170-8174.
48. Premawardhena A, Fisher CA, Fathiu F, et al. Genetic determinants of jaundice and gallstones, in haemoglobin E beta thalassaemia. Lancet. 2001:357:1945-1946.
49. Premawardhena A, Fisher CA, Liu YT, et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis. 2003;31:98-101.
50. Bosma PJ, van der Meer IM, Bakker CT, Hofman A, Paul-Abrahamse M, Witteman JC. UGT1A1*28 allele and coronary heart disease: the Botterdam Study. Clin Chem. 2003;11:1296-1297.
51. Hall D, Ybazeta G, Destro-Bisol G, Petzi-Erler M, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics. 1999;9:591-599.
52. Innocenti F, Grimsley C, Das S, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 2002;12:725-733.
53. Jinno H, Tanaka-Kagawa T, Hanioka N, et al. Glucuroniidation of 7-ethyl10-hydroxycamprothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos. 2003;31:108-113.
54. Akaba K, Kimura T, Sasaki A, et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glocuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int. 1998;46:21-26.
55. Huang CS, Luo GA, Huang ML, Yu SC, Yang SS. Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese. Pharmacogenetics 2000;10:539-544.
56. Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with reduced glucuronidation mid increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther. 2004;75:501-515.
57. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Retain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994;54:3723-3725.
58. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 1999;65: 576-582.
59. Iyer L, Das S, Janisch L, et al. UGT1A1 *28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2:43-47.
60. Marcuello E, Altes A, del Rio E, Cesar A, Menoyo A, Baiget M. Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer. 2004; 112:733-737.
61. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res. 2004;10:5151-5159.
62. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061-3068.
63. Hasegawa Y, Sarashina T, Ando M, et al. Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin Chem. 2004;50: 1479-1480.
64. Lyamichev V, Mast AL, Hall JG, et al. Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol. 1999;17:292-296.
65. Gagne JF, Montminy V, Belanger P, Journault K. Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol. 2002;62:608-617.
66. Ciotti M. Basu N, Brangi M, Owens IS. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun. 1999;260:199-202.
67. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol. 2000;40:581-616.
68. Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005;11:1226-1236.
69. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinorecan and cisplatin. J Clin Oncol. 2006;24:2237-2244.
70. Innocenti F. Liu W, Chen P, Desai AA, Das S, Ratain MJ. Haplotypes of variants in the UDP-Glucuronosyltransferasr1A9 and 1A1 genes. Pharmacogenet Genomics. 2005;15:295-301.
71. Innocenti F. Undevia S, Chen X, et al. Pharmacogenetic analysis of inter-individual irinotecan (CPT-11) phamacokinetic (PK) variability: evidence for a functional variant of ABCC2. J Clin Oncol. 2004:22(14s):2010.
72. de Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther. 2007;81:42-49.
73. Sai K, Kaniwa N, Itoda M, et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics. 2003;13:741-757.
74. Zhou Q, Sparreboom A, Tan EH, et al. Pharmacogenctic Profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol. 2005;59:415-424.
75. Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to die 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol. 1997;53:171-178.
76. Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical tria1. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;791:245-253.
77. Nishiyama T, Ogura & Nakano H, et al. Reverse geometrical selecuvity in glucuronidation and sulfation of cis and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol. 2002;63:1817-1830.
78. Falany JL, Pilloff DE, Leyh TS, Falany CN. Sulfation of raloxifene arid 4-hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab Dispos. 2006;34:361-368.
79. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95:1758-1764.
80. Lennard MS. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacol Toxicol. 1990;67:273-283.
81. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229-243.
82. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999;9:669-682.
83. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295.
84. Nowell SA, Ahn J, Rae JM, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat. 2005:91:249-258.
85. Wegman R Vainikka L, Stal O, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 2005;7:284-290.
86. Nowell S, Sweeney C, Winters M, et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst. 2002; 94:1635-1640.
87. Bonanni B, Macis D, Maisonneuve P et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol. 2006;24:3708-3709; author reply 3709.
88. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23:9312-9318.
89. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 2007; 9:R7.
90. Reynolds S. SPORE Study Provides New Guidelines for Tamoxifen Use. NCI Cancer Bulletin. 2006;3:1-2.
91. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther. 1993;53:410-418.
92. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 2002;72:76-89.
93. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994;46:452-459.
94. McLellan RA, Oscason M, Seidegard J, Evans DA, Ingehnan-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics. 1997:7:187-191.
95. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002;201S-13S.
96. Thatcher N, Chang A, Parikh R et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527-1537.
97. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
98. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
99. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are pommon in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-13311.
100. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21:2237-2246.
101. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513-2520.
102. Han SW Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell rung cancer patients treated with gefitinib. J Clin Oncol. 2005;23:2493-2501.
103. Cortes-Funes H, Gomez C, Rosell R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol. 2005;16:1081-1086.
104. Taron M, Ichinose Y. Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005; 11:5878-5885.
105. Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer. 2006;95:1483-1489.
106. Inoue A, Suzuki T, Pukuhara T, et al. Prospective phase II study of gefitinib for chemotheraphy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006;24: 3340-3346.
107. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 2006;95:998-1004.
108. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23:6829-6837.
109. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643-655.
110. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006;24:5034-5042.
111. Kobayashi S, Boggon TJ, Dayaram T, et al. EQFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786-792.
112. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17.
113. Innocenti F, Vokes EE, Ratain MJ. Irinogenetics: what is the right star? J Clin Oncol. 2006;24:2221-2224.
114. Innocenti F, Janisch L, Das S, et al. A genotype-directed phase I study of irinotecan in advanced cancer patients. J Clin Oncol 2007;25(185):2502.
115. Goetz MP, Safgren S, Goldberg RM, et al. A phase I dose escalation study of irinotecan (CPT-11), oxaliplatin (Oxal), and capecitabine (Cap) within three UGT1A1 TA promoter cohorts (6/6, 617, and 7/7). J Clin Oncol. 2005;23(16S):2014.
116. Falandry C, You B, Milano G, et al. Individual genotyping to optimize chemotheraphy in metastatic colorectal cancer (MCRC): the COLOGEN trial. J Clin Oncol. 2007;25(18S):2510.